Latest & greatest articles for adalimumab

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on adalimumab or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on adalimumab and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for adalimumab

141. Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis

Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis Xie F, Blackhouse G, Assasi N, Gaebel K, Robertson D, Goeree R Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods (...) strategies were usual care, infliximab 5mg per kg with a switch to adalimumab if there was no response or if the response was lost during maintenance therapy, and infliximab 5mg per kg with a switch to 10mg per kg if there was no response and a switch to adalimumab if the response was lost during maintenance therapy. Both the infliximab and adalimumab strategies consisted of initial treatment at weeks zero, two, and six, followed by maintenance treatment every eight weeks. The usual care was conventional

NHS Economic Evaluation Database.2009

142. Cost-effectiveness of adalimumab for the maintenance of remission in patients with Crohn's disease

Cost-effectiveness of adalimumab for the maintenance of remission in patients with Crohn's disease Cost-effectiveness of adalimumab for the maintenance of remission in patients with Crohn's disease Cost-effectiveness of adalimumab for the maintenance of remission in patients with Crohn's disease Loftus EV, Johnson SJ, Yu AP, Wu EQ, Chao J, Mulani PM Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains (...) a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study investigated the cost-effectiveness of a new monoclonal antibody, adalimumab, compared with the usual non-biologic therapies, for the maintenance treatment of patients with severe or moderate-to-severe active Crohn’s disease. The authors concluded that adalimumab was cost-effective. Despite some limitations, the methods

NHS Economic Evaluation Database.2009

143. Adalimumab (Humira) for Crohns Disease

Adalimumab (Humira) for Crohns Disease Adalimumab (Humira) for Crohns Disease Adalimumab (Humira) for Crohns Disease Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Report may be purchased from . Citation Adalimumab (Humira) for Crohns Disease . Lansdale: HAYES, Inc.. 2009 Authors' objectives Adalimumab (D2E7, Humira®; Abbott Laboratories) is a recombinant human

Health Technology Assessment (HTA) Database.2009

145. Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: Results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two

Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: Results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two 18576337 2008 07 15 2008 08 08 2016 11 24 0004-3591 58 7 2008 Jul Arthritis and rheumatism Arthritis Rheum. Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve-week (...) randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two. 1981-91 10.1002/art.23606 To evaluate the efficacy and safety of the tumor necrosis factor (TNF) antagonist adalimumab in patients with axial spondylarthritis (SpA) without radiographically defined sacroiliitis refractory to conventional treatment. Patients with active axial SpA (n = 46) were randomized to receive placebo or adalimumab at a dosage of 40 mg subcutaneously every other week for 12

EvidenceUpdates2008

147. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial 17936411 2007 12 26 2008 01 09 2015 11 19 1097-6787 58 1 2008 Jan Journal of the American Academy of Dermatology J. Am. Acad. Dermatol. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. 106-15 Adalimumab is a fully human monoclonal antibody that binds tumor necrosis factor, a key proinflammatory cytokine involved in the pathogenesis of psoriasis. We sought (...) to evaluate clinical efficacy and safety of adalimumab for moderate to severe psoriasis and investigate continuous versus interrupted therapy. We conducted a 52-week, multicenter study of 1212 patients randomized to receive adalimumab (40 mg) or placebo every other week for the first 15 weeks. At least 75% improvement in the Psoriasis Area and Severity Index (PASI) score was the criterion for advancement through this multiphase study. At week 16, 71% (578 of 814) of adalimumab- and 7% (26 of 398

EvidenceUpdates2008

149. Review: azathioprine, infliximab, certolizumab, and adalimumab are effective for maintaining remission in Crohn’s disease

Review: azathioprine, infliximab, certolizumab, and adalimumab are effective for maintaining remission in Crohn’s disease Review: azathioprine, infliximab, certolizumab, and adalimumab are effective for maintaining remission in Crohn’s disease | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user (...) name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: azathioprine, infliximab, certolizumab, and adalimumab are effective for maintaining remission in Crohn’s disease Article Text Therapeutics Review: azathioprine, infliximab, certolizumab, and adalimumab are effective for maintaining remission in Crohn’s

Evidence-Based Medicine (Requires free registration)2008

150. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis.

Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. 18716298 2008 08 21 2008 08 28 2015 11 19 1533-4406 359 8 2008 Aug 21 The New England journal of medicine N. Engl. J. Med. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. 810-20 10.1056/NEJMoa0706290 Tumor necrosis factor (TNF) has a pathogenic role in juvenile rheumatoid arthritis. We evaluated the efficacy and safety of adalimumab, a fully human monoclonal anti-TNF antibody, in children (...) with polyarticular-course juvenile rheumatoid arthritis. Patients 4 to 17 years of age with active juvenile rheumatoid arthritis who had previously received treatment with nonsteroidal antiinflammatory drugs underwent stratification according to methotrexate use and received 24 mg of adalimumab per square meter of body-surface area (maximum dose, 40 mg) subcutaneously every other week for 16 weeks. We randomly assigned patients with an American College of Rheumatology Pediatric 30% (ACR Pedi 30) response at week

NEJM2008

151. Adalimumab, etanercept and infliximab for ankylosing spondylitis (TA143)

Adalimumab, etanercept and infliximab for ankylosing spondylitis (TA143) Adalimumab, etanercept and infliximab for ankylosing spondylitis | Guidance and guidelines | NICE Adalimumab, etanercept and infliximab for ankylosing spondylitis Technology appraisal guidance [TA143] Published date: 28 May 2008 Guidance . Explore Guidance app Copyright © 2017 National Institute for Health and Care Excellence. All rights reserved.

National Institute for Health and Clinical Excellence - Technology Appraisals2008

152. Adalimumab for the treatment of adults with psoriasis (TA146)

Adalimumab for the treatment of adults with psoriasis (TA146) Adalimumab for the treatment of adults with psoriasis | Guidance and guidelines | NICE Adalimumab for the treatment of adults with psoriasis Technology appraisal guidance [TA146] Published date: 25 June 2008 Share Guidance wherever possible. Explore Guidance app Copyright © 2017 National Institute for Health and Care Excellence. All rights reserved.

National Institute for Health and Clinical Excellence - Technology Appraisals2008

154. Adalimumab, etanercept, and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation

Adalimumab, etanercept, and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation Adalimumab, etanercept, and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation Journals Library An error has occurred in processing the XML document An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please

NIHR HTA programme2007

155. The number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: a systematic literature review

The number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: a systematic literature review The number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: a systematic literature review The number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response (...) in three randomized controlled trials on established rheumatoid arthritis: a systematic literature review Kristensen LE, Christensen R, Bliddal H, Geborek P, Danneskiold-Samsoe B, Saxne T CRD summary This review compared tumour necrosis factor-alpha blocking drugs for rheumatoid arthritis and concluded that adalimumab, etanercept and infliximab had similar efficacy, but infliximab may need higher doses for a similar effect. Given that this was based on an indirect comparison of only one trial of each

DARE.2007

156. Cost effectiveness of adalimumab for the treatment of ankylosing spondylitis in the United Kingdom

Cost effectiveness of adalimumab for the treatment of ankylosing spondylitis in the United Kingdom Cost effectiveness of adalimumab for the treatment of ankylosing spondylitis in the United Kingdom Cost effectiveness of adalimumab for the treatment of ankylosing spondylitis in the United Kingdom Botteman MF, Hay JW, Luo MP, Curry AS, Wong RL, van Hout BA Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains (...) a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the cost-effectiveness of adalimumab versus conventional therapy for the treatment of ankylosing spondylitis. The authors concluded that adalimumab was cost-effective from the perspective of the UK National Health Service, especially if the British Society of Rheumatology treatment guidelines were followed

NHS Economic Evaluation Database.2007

157. Quality of life and economic impact of switching from established infliximab therapy to adalimumab in patients with rheumatoid arthritis

Quality of life and economic impact of switching from established infliximab therapy to adalimumab in patients with rheumatoid arthritis Quality of life and economic impact of switching from established infliximab therapy to adalimumab in patients with rheumatoid arthritis Quality of life and economic impact of switching from established infliximab therapy to adalimumab in patients with rheumatoid arthritis Walsh C A, Minnock P, Slattery C, Kennedy N, Pang F, Veale D J, Bresnihan B, FitzGerald (...) ' therapy) to adalimumab. The mean infliximab dosage was 5 mg/kg every 8 weeks. When patients were switched to adalimumab they received 40 mg subcutaneously every other week. One-year extrapolation data were also presented. Type of intervention Treatment. Economic study type Cost-effectiveness analysis Study population Eligible individuals were those with RA and responders to at least 12 weeks' infliximab, but with ongoing, varying levels of disease activity. They had to be willing to self-administer

NHS Economic Evaluation Database.2007

158. Infliximab dose escalation vs initiation of adalimumab for loss of response in Crohn's disease: a cost-effectiveness analysis

Infliximab dose escalation vs initiation of adalimumab for loss of response in Crohn's disease: a cost-effectiveness analysis Infliximab dose escalation vs initiation of adalimumab for loss of response in Crohn's disease: a cost-effectiveness analysis Infliximab dose escalation vs initiation of adalimumab for loss of response in Crohn's disease: a cost-effectiveness analysis Kaplan G G, Hur C, Korzenik J, Sands B E Record Status This is a critical abstract of an economic evaluation that meets (...) the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The study objective was to determine if dose escalation of infliximab was cost-effective in comparison with adalimumab initiation after loss of response to infliximab in patients with Crohn’s disease. The authors concluded that dose escalation would yield more quality

NHS Economic Evaluation Database.2007

159. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation

Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation McLeod C, Bagust A, Boland A, Dagenais P, Dickson R, Dundar Y, et al Record Status This is a bibliographic record (...) of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation McLeod C, Bagust A, Boland A, Dagenais P, Dickson R, Dundar Y, et al. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation. Health Technology Assessment 2007; 11(28): 1-158 Authors' objectives "The objectives of this review were to assess the comparative clinical effectiveness

Health Technology Assessment (HTA) Database.2007

160. Adalimumab, alefacept, efalizumab, etanercept, and infliximab for severe psoriasis vulgaris in adults: budget impact analysis and review of comparative clinical- and cost-effectiveness

Adalimumab, alefacept, efalizumab, etanercept, and infliximab for severe psoriasis vulgaris in adults: budget impact analysis and review of comparative clinical- and cost-effectiveness Adalimumab, alefacept, efalizumab, etanercept, and infliximab for severe psoriasis vulgaris in adults: budget impact analysis and review of comparative clinical- and cost-effectiveness Adalimumab, alefacept, efalizumab, etanercept, and infliximab for severe psoriasis vulgaris in adults: budget impact analysis (...) and review of comparative clinical- and cost-effectiveness Boudreau R, Blackhouse G, Goeree R, Mierzwinski-Urban M Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Boudreau R, Blackhouse G, Goeree R, Mierzwinski-Urban M. Adalimumab, alefacept, efalizumab, etanercept, and infliximab for severe psoriasis vulgaris in adults: budget impact analysis

Health Technology Assessment (HTA) Database.2007